PALATIN TECHNOLOGIES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
PALATIN TECHNOLOGIES, INC. (PTN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $480.12 per share for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-05-13
- PALATIN TECHNOLOGIES, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-09-30 was $111.61.
- PALATIN TECHNOLOGIES, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-09-30 was $0.00.
- PALATIN TECHNOLOGIES, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2022-09-30 was $12.17, a 1638.57% increase year-over-year.
- PALATIN TECHNOLOGIES, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- PALATIN TECHNOLOGIES, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $189.50, a 1479.17% increase from fiscal 2023.
- PALATIN TECHNOLOGIES, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $12.00, a 28.01% decline from fiscal 2022.
- PALATIN TECHNOLOGIES, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $16.67, a 11.09% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $480.12 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $487.56 10-Q · filed 2026-02-17 | ||||
| 2025-09-30 | $111.61 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $0.00 10-K · filed 2025-09-23 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $189.50 10-K · filed 2025-09-23 | $3.79 10-K · filed 2024-09-30 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | $0.00 10-Q · filed 2024-02-14 | ||||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $12.00 10-K · filed 2024-09-30 | ||||
| 2023-03-31 | $12.00 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $12.24 10-Q · filed 2023-02-14 | ||||
| 2022-09-30 | $12.17 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $16.67 10-K · filed 2023-09-28 | ||||
| 2022-03-31 | $0.69 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $0.70 10-Q · filed 2022-02-14 | ||||
| 2021-09-30 | $0.70 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $18.75 10-K · filed 2022-09-22 | $0.75 10-K · filed 2021-09-28 | |||
| 2021-03-31 | $0.75 10-Q · filed 2021-05-14 | ||||
| 2020-12-31 | $0.74 10-Q · filed 2021-02-16 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-16 | ||||
| 2020-06-30 | $0.86 10-K · filed 2021-09-28 | ||||
| 2020-03-31 | $1.03 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | $0.00 10-Q · filed 2020-02-10 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $0.62 10-K · filed 2020-09-25 | ||||
| 2019-03-31 | $0.54 10-Q · filed 2019-05-09 | ||||
| 2018-12-31 | $0.53 10-Q · filed 2019-02-11 | ||||
| 2018-09-30 | $0.53 10-Q · filed 2018-11-09 | ||||
| 2018-06-30 | $1.70 10-K · filed 2020-09-25 | ||||
| 2017-06-30 | $1.12 10-K · filed 2019-09-12 | ||||
| 2016-06-30 | $0.80 10-K · filed 2018-09-13 | ||||
| 2015-06-30 | $1.92 10-K · filed 2017-09-25 | ||||
| 2014-06-30 | $0.68 10-K · filed 2016-09-19 | ||||
| 2013-06-30 | $5.20 10-K · filed 2015-09-18 | ||||
| 2012-06-30 | $3.64 10-K · filed 2014-09-12 | $33.07 10-K · filed 2012-09-10 | |||
| 2011-06-30 | $10.02 10-K · filed 2013-09-27 | $41.14 10-K · filed 2012-09-10 | |||
| 2010-06-30 | $34.10 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |